MEDIPOST Co., Ltd.

As of March 31, 2026, MEDIPOST Co., Ltd. carries a market capitalization of 828.61B, placing it among publicly traded companies globally. Its enterprise value stands at 766.29B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

MEDIPOST Co., Ltd.'s next confirmed earnings release is scheduled for November 12, 2026.

As of March 31, 2026, MEDIPOST Co., Ltd. has 39.09M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 10.33, and the price-to-book ratio stands at 3.45.

These figures are as of March 31, 2026. The EV/Sales ratio of 10.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 766.29B versus a market cap of 828.61B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, MEDIPOST Co., Ltd. maintains a current ratio of 1.08, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 64.07, indicating elevated leverage, while an interest coverage ratio of -11.21 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, MEDIPOST Co., Ltd. posted a negative return on equity (ROE) of -33.44, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.30, reflecting losses generated across the asset base. The company generates approximately 221.91M in revenue per employee across its workforce of 333.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.42 indicates how many times MEDIPOST Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, MEDIPOST Co., Ltd. recorded 747.56M in income tax expense. The company reported a pretax loss of -79.44B and -79.57B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, MEDIPOST Co., Ltd.'s stock has declined approximately 40.85% over the past 52 weeks. The 50-day moving average sits at 9,171.00, while the 200-day moving average is 15,170.65.

Over the twelve months ended March 31, 2026, MEDIPOST Co., Ltd. generated 73.90B in revenue and converted that into -79.57B in net income, yielding earnings per share of -2,226.77. EBITDA reached -65.59B, while operating income came in at -71.17B.

As of March 31, 2026, MEDIPOST Co., Ltd. holds 217.66B in cash and equivalents against 154.58B in total debt, resulting in a net debt position of 50.43B. Total book value stands at 240.50B, with working capital of 20.04B providing operational flexibility.

MEDIPOST Co., Ltd. produced -54.22B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -4.78B in capital expenditures, free cash flow totaled -59.00B - equivalent to -1,638.31 per share.

Over the twelve months ended March 31, 2026, MEDIPOST Co., Ltd. posted a gross margin of 63.46, reflecting its pricing power and cost economics. The operating margin of -96.31 and net profit margin of -107.68 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -7.73: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -24.50, meaning MEDIPOST Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

MEDIPOST Co., Ltd.'s most recent stock split took place on September 19, 2023 with a 298:339 split ratio.

As of March 31, 2026, MEDIPOST Co., Ltd. has an Altman Z-Score of 0.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.